secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001493152-24-011024
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX Therapeutics reports FY2023 net loss $14.8M; cash only $0.3M; going concern doubt
--------------------------------------------------------------------------------

- Net loss $14.8M in FY2023 vs $10.5M in FY2022; EPS ($13.73) vs ($9.70) (basic/diluted).
- Cash and equivalents $0.3M at Dec 31, 2023; $4.5M owed to Juvenescence under line of credit.
- Operating expenses rose to $10.1M from $7.0M, mainly due to merger due diligence and legal fees.
- AgeX expresses substantial doubt about going concern; cash insufficient for next 12 months.
- Stockholders approved merger with Serina Therapeutics; line of credit increased $4.4M, repayment extended to May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224011024/0001493152-24-011024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224011024/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer